Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Viral Conjunctivitis Pipeline Drugs Market Overview
Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.
The Viral conjunctivitis – drugs in development research report provides a comprehensive overview on the therapeutics under development for Viral conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral conjunctivitis and features dormant and discontinued projects.
Key Targets | Cellular Tumor Antigen p53, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, DNA Polymerase, and Serine/Threonine Protein Kinase UL97 |
Key Mechanisms of action | Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, DNA Polymerase Inhibitor, Serine/Threonine Protein Kinase UL97 Inhibitor |
Key Routes of Administration | Ophthalmic, Oral, Topical, Vaginal,Inhalational, Intravitreal, Nasal |
Key Molecule Types | Small Molecule, and Recombinant Enzyme |
Major Companies | Okogen Inc, Invirsa Inc, IVIEW Therapeutics Inc, Kiora Pharmaceuticals Inc, Microbiotix Inc, NanoViricides Inc, Plex Pharmaceuticals Inc, Starpharma Holdings Ltd, and TGV-Inhalonix Inc |
Key Targets in the Viral Conjunctivitis Pipeline Drugs Market
The key targets in the Viral Conjunctivitis pipeline drugs market are Cellular Tumor Antigen p53, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, DNA Polymerase, and Serine/Threonine Protein Kinase UL97.
Viral Conjunctivitis Pipeline Drugs Market, by Targets, 2021 (%)
For more target insights, download a free report sample
Key MoA in the Viral Conjunctivitis Pipeline Drugs Market
The key mechanisms of action in the Viral Conjunctivitis pipeline drugs market are Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, DNA Polymerase Inhibitor, and Serine/Threonine Protein Kinase UL97 Inhibitor.
Viral Conjunctivitis Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Viral Conjunctivitis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Viral Conjunctivitis pipeline drugs market are Ophthalmic, Oral, Topical, Vaginal, Inhalational, Intravitreal, and Nasal.
Viral Conjunctivitis Pipeline Drugs Market Analysis, by RoA, 2021 (%)
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Viral Conjunctivitis Pipeline Drugs Market
The key molecule types in the Viral Conjunctivitis pipeline drugs market are Small Molecule, and Recombinant Enzyme.
Viral Conjunctivitis Pipeline Drugs Market, by Molecule Type, 2021 (%)
To get more insights on key molecule types, download a free sample report
Major Companies in the Viral Conjunctivitis Pipeline Drugs Market
The major companies in the Viral Conjunctivitis pipeline drugs market are Okogen Inc, Invirsa Inc, IVIEW Therapeutics Inc, Kiora Pharmaceuticals Inc, Microbiotix Inc, NanoViricides Inc, Plex Pharmaceuticals Inc, Starpharma Holdings Ltd, and TGV-Inhalonix Inc.
Starpharma Holdings: Ltd Starpharma Holdings Ltd (Starpharma) is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company’s development programs include its DEP drug delivery, which is built around dendrimers, and VivaGel portfolio. Its flagship product candidate, VivaGel, is a gelbased formulation for the treatment and prevention of bacterial vaginosis (BV).
Viral Conjunctivitis Pipeline Drugs Market, by Major Companies, 2021 (%)
For more company insights, download a free sample report
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis
- The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Viral Conjunctivitis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Viral Conjunctivitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Viral Conjunctivitis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
IVIEW Therapeutics Inc
Kiora Pharmaceuticals Inc
Microbiotix Inc
NanoViricides Inc
Okogen Inc
Plex Pharmaceuticals Inc
Starpharma Holdings Ltd
TGV-Inhalonix Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Viral Conjunctivitis pipeline drugs market?
The key targets in the Viral Conjunctivitis pipeline drugs market are Cellular Tumor Antigen p53, Dihydroorotate Dehydrogenase (Quinone) Mitochondrial, DNA Polymerase, and Serine/Threonine Protein Kinase UL97.
-
What are the key mechanisms of action in the Viral Conjunctivitis pipeline drugs market?
The key mechanisms of action in the Viral Conjunctivitis pipeline drugs market are Dihydroorotate Dehydrogenase (Quinone) Mitochondrial Inhibitor, DNA Polymerase Inhibitor, Serine/Threonine Protein Kinase UL97 Inhibitor.
-
What are the key routes of administration in the Viral Conjunctivitis pipeline drugs market?
The key routes of administration in the Viral Conjunctivitis pipeline drugs market are Ophthalmic, Oral, Topical, Vaginal, Inhalational, Intravitreal, Nasal.
-
What are the key molecule types in the Viral Conjunctivitis pipeline drugs market?
The key molecule types in the Viral Conjunctivitis pipeline drugs market are Small Molecule, and Recombinant Enzyme.
-
What are the major companies in the Viral Conjunctivitis pipeline drugs market?
The major companies in the Viral Conjunctivitis pipeline drugs market are Okogen Inc, Invirsa Inc, IVIEW Therapeutics Inc, Kiora Pharmaceuticals Inc, Microbiotix Inc, NanoViricides Inc, Plex Pharmaceuticals Inc, Starpharma Holdings Ltd, and TGV-Inhalonix Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.